European Union - English - EMA (European Medicines Agency)

recordati netherlands b.v. - dinutuximab beta - neuroblastoma - antineoplastic agents - qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures.in patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, qarziba should be combined with interleukin 2 (il 2).

Canada - English - Health Canada

amgen canada inc - blinatumomab - powder for solution - 38.5mcg - blinatumomab 38.5mcg - antineoplastic agents

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - polatuzumab vedotin - injection, powder, lyophilized, for solution - polatuzumab vedotin 140 mg

Canada - English - Health Canada

incyte corporation - tafasitamab - powder for solution - 200mg - tafasitamab 200mg - antineoplastic agents

European Union - English - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastic agents - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - polatuzumab vedotin - injection, powder, lyophilized, for solution - polatuzumab vedotin 30mg/vial

Canada - English - Health Canada

gilead sciences canada inc - sacituzumab govitecan - powder for solution - 180mg - sacituzumab govitecan 180mg - antineoplastic agents

Canada - English - Health Canada

kyowa kirin, inc. - mogamulizumab - solution - 4mg - mogamulizumab 4mg

Israel - English - Ministry of Health

medison pharma ltd - mogamulizumab - concentrate for solution for infusion - mogamulizumab 4 mg / 1 ml - mogamulizumab - poteligeo is indicated for the treatment of adult patients with mycosis fungoides (mf) or sézary syndrome (ss) who have received at least one prior systemic therapy.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - belantamab mafodotin - powder for concentrate for solution for infusion - belantamab mafodotin 100 mg - belantamab - blenrep is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-cd38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.